Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis

doi:10.1007/s10528-021-10151-x

	Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis
	Wu, Hao; Xia, Liming; Xu, Haichao
刊名	BIOCHEMICAL GENETICS
	2021-11-18
关键词	FUS-CHOP Myxoid liposarcoma Apoptosis miR-486 CDK4 axis
ISSN号	0006-2928
DOI	10.1007/s10528-021-10151-x
通讯作者	Xia, Liming(drlmx1340@163.com)
英文摘要	This study aimed to explore the roles and relationship between FUsed in Sarcoma (FUS)-C/EBP HOmologous Protein (CHOP), microRNA (miR)-486 and cyclin dependent kinase 4 (CDK4) in myxoid liposarcoma, and determined whether FUS-CHOP can regulate proliferation and apoptosis of myxoid liposarcoma cells by regulating miR-486/CDK4 axis. The levels of miR-486, CDK4 and FUS-CHOP in myxoid liposarcoma samples/adjacent normal muscle tissues and myxoid liposarcoma/human adipose-derived stem cell line were evaluated using reverse transcription-quantitative polymerase chain reaction and western blotting. Cell proliferation and apoptosis were performed using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide and flow cytometry, respectively. Furthermore, the apoptosis-related proteins were determined using Western blot assay. We found that miR-486 was down-regulated, FUS-CHOP and CDK4 were up-regulated in myxoid liposarcoma tissues and myxoid liposarcoma cell lines. Moreover, FUS-CHOP-siRNA distinctly suppressed FUS-CHOP level and increased miR-486 levels in 1955/91 cells. Our results demonstrated that knockdown of FUS-CHOP by siRNA inhibited 1955/91 growth, promoted cell apoptosis and enhanced cleaved Caspase3 protein expression. However, all these data were reversed by miR-486 inhibitor. Similarly, compared to mimic control, miR-486 mimic markedly reduced 1955/91 cells growth, induced cell apoptosis and fortified cleaved Caspase3 level, while these results were abolished by CDK4-plasmid. Collectively, our observations clearly suggested that FUS-CHOP regulated myxoid liposarcoma cell proliferation and apoptosis by the regulation of miR-486/CDK4 axis, indicating the potential use of FUS-CHOP-siRNA as a promising therapy for myxoid liposarcoma.
资助项目	Zhejiang Medical and Health Science and Technology Plan Project[2017KY249] ; Zhejiang Medical and Health Science and Technology Plan Project[2019KY332]
WOS关键词	EXPRESSION ; MALIGNANCY ; REGULATOR ; CANCER ; CDK4
WOS研究方向	Biochemistry & Molecular Biology ; Genetics & Heredity
语种	英语
出版者	SPRINGER/PLENUM PUBLISHERS
WOS记录号	WOS:000720201200003
资助机构	Zhejiang Medical and Health Science and Technology Plan Project
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126608]
专题	中国科学院合肥物质科学研究院
通讯作者	Xia, Liming
作者单位	Chinese Acad Sci, Inst Basic Med & Canc IBMC, Bone & Soft Tissue Sarcoma Dept, Canc Hosp,Univ Chinese Acad Sci,Zhejiang Canc Hos, 1 Banshan East Rd, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Wu, Hao,Xia, Liming,Xu, Haichao. Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis[J]. BIOCHEMICAL GENETICS,2021.
APA	Wu, Hao,Xia, Liming,&Xu, Haichao.(2021).Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.BIOCHEMICAL GENETICS.
MLA	Wu, Hao,et al."Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis".BIOCHEMICAL GENETICS (2021).